Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Leptomeningeal Metastases
NCT02939300Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in leptomeningeal carcinomatosis (LMC), sponsored by Massachusetts General Hospital. Primary endpoint: Overall Survival at 3 months. Started Feb 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
leptomeningeal carcinomatosis (LMC)
Beyond the preview
Go deeper on NCT02939300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939300.